pharma · metastatic squamous non-small cell lung cancer
CureVac
CureVac AG
CureVac AG is a pharma organization headquartered in EU. Primary therapeutic focus areas include metastatic squamous non-small cell lung cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent
Tübingen, DE HQ
2000 Founded
639 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Tübingen, DE
- Founded
- 2000
- Employees
- 639
- Programs
- 1
- Drugs
- 2
- Patents
- 0
CV-HNLC-001
Phase 1 · other · metastatic squamous non-small cell lung cancer
CV-HNLC-001 for metastatic squamous non-small cell lung cancer is a Phase 1 program (other) at CureVac AG with 1 ClinicalTrials.gov record(s).
Internal code CV-HNLC-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CureVac AG
- Phase
- Phase 1
- Modality
- other
- Indication
- metastatic squamous non-small cell lung cancer
- Status
- active
- Trials
- 1